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Abstract 
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. HCC has a 
poor prognosis associated with tumor recurrence and drug resistance, which has been attributed to the existence of 
hepatic cancer stem cells (HCSCs). However, the characteristics and regulatory mechanisms of HCSCs remain unclear. 
We therefore established a novel system to enrich HCSCs and we demonstrate that these HCSCs exhibit cancer stem 
cell properties.
Methods: We used miRNA and mRNA high-throughput sequencing data sets to determine molecular signatures 
and regulatory mechanisms in HCSCs. Paired miRNA and gene deep sequencing data in HCSCs versus HCC cells were 
used to identify candidate biomarkers of HCSCs. Using network analysis, we studied the relationship between miRNA 
and gene biomarkers, and KEGG pathway enrichment analysis was performed to study the function of candidate 
biomarkers.
Results: We identified 9 up- and 9 down-regulated miRNAs and 115 up- and 402 down-regulated genes in HCSCs 
compared with HCC cells. A miRNA-gene network was constructed using 651 miRNA–gene interactions (between 7 
up-regulated miRNAs and 274 down-regulated genes), and 103 miRNA–gene interactions (between 9 down-regu-
lated miRNAs and 62 up-regulated genes). Pathway enrichment analysis identified five tumor invasion- and metasta-
sis-related pathways and MAPK signaling associated with HCSCs. We further discovered two novel pathways that likely 
play a role in the regulation of HCSCs.
Conclusions: We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with 
potential diagnostic and therapeutic value.
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Background
Hepatocellular carcinoma (HCC) is one of the most 
common malignancies that accounts for 70–85% of liver 
cancers worldwide [1]. Although significant progress 
has been made in recent years regarding the treatment 
options for HCC, poor prognosis remains a problem 
because of late diagnosis, recurrence, and drug resistance 
[2]. While surgical intervention–the main treatment 
option for HCC–is effective in patients diagnosed at an 
early stage [3], the treatment of advanced liver cancer is 
more difficult and prognosis remains poor because of 
drug resistance [4], making recurrence almost inevitable 
[5]. Cancer stem cells (CSCs), which are critical for the 
initial growth and maintenance of the tumor, have been 
identified in liver cancers [6–8]. Recently, CSCs have 
been associated with tumor recurrence and drug resist-
ance in HCC [9, 10]. CSCs are potential targets for HCC 
diagnosis and treatment–it is therefore crucial that we 
study the regulatory mechanisms of CSCs.
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Several biological markers of hepatic cancer stem cells 
(HCSCs), including CD133 [10], CD90 [11], and EpCAM 
[12] have been identified. However, the characteristics 
and regulatory mechanisms of HCSCs remain unclear. 
We therefore established a novel system to enrich HCSCs 
and previously reported that these cells have CSC charac-
teristics [13].
MicroRNAs (miRNAs), a class of small non-coding 
RNAs, have been shown to play an important role in a 
variety of biological processes. Abnormal expression 
of miRNAs may impact the expression of hundreds of 
genes. Recently, with the development of microarray 
and high-throughput sequencing technology, miRNA–
mRNA interactions in cancers and other biological pro-
cesses have been extensively studied [14–16]. However, 
genome-wide miRNA–mRNA interactions in HCSCs 
remain largely unknown.
In this study, we performed high-throughput 
sequencing of HCSC small RNA and mRNA, and inte-
grated miRNA and mRNA data to identify biomarkers 
of HCSCs and to unravel HCSC regulatory networks. 




We used two human hepatoma cell lines (Hep3B and 
Huh7) from the American Type Culture Collection 
(ATCC) to culture stem-like cancer cells. We previ-
ously demonstrated that these cells have enhanced stem 
cell properties, drug resistance, properties of epithelial 
mesenchymal transition, and enhanced tumor-initiat-
ing capabilities [13]. Here, we analyzed the regulatory 
mechanism of these two types of HSCSc using miRNA 
and RNA sequencing data. MiRNA and gene expres-
sion data of hepatic cancer stem cells and cancer cells 
were sequenced using the Illumina Genome Analyzer, to 
a depth of 30-fold coverage. Details of the data sets are 
shown in Table 1.
Small RNA and mRNA libraries were sequenced on 
an Illumina Genome Analyzer II (Illumina, San Diego, 
CA, USA) according to the manufacturer’s instruc-
tions. Raw RNAseq reads were filtered for adapters 
and/or low-quality reads, followed by alignment to the 
Fig. 1 The network analysis pipeline.
Table 1 Details of data sets
Paired miRNA and gene deep sequencing datasets from the same sample of 
two hepatic cancer stem cells and two hepatic cancer cells were used. Detailed 
information about these datasets is provided in this table.
Data type Cell line Total reads Normalized
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human genome (NCBI Build 36.1) using NextGENe® 
software (Softgenetics, State College, PA, USA). Reads 
mapping to individual transcripts were counted digi-
tally, and the expression levels for each gene were 
normalized using reads per kilobase of exon model 
per million mapped reads (RPKM) [17]. For small 
RNA analysis, after filtering contaminant and redun-
dant reads, and reads smaller than 18 nt, clean reads 
were mapped to the human genome (NCBI Build 36.1) 
using SOAP [18]. Reads were then mapped to Riboso-
mal RNA (rRNA), Small cytoplasmic RNA (scRNA), 
small nuclear RNA (snRNA), small nucleolar RNA 
(snoRNA), and transfer RNA (tRNA) from GenBank. 
The remaining reads were searched against miRBase 
(release 17) [19]. Read counts of the annotated miR-
NAs were normalized using transcripts per million 
(TPM) [20].
Differential expression analysis
Genes and miRNAs differentially expressed between 
hepatic cancer stem cells and hepatic cancer cells were 
identified by calculating fold change values and using an 
established statistical method based on the Poisson dis-
tribution [21–23] to calculate p-values. The Benjamini–
Hochberg FDR method [24] was used to adjust p-values 
for multiple testing. MiRNAs and genes with an absolute 
log2 fold-change (expression of cancer stem cells/expres-
sion of cancer cells) ≥1 and an FDR ≤0.01 were consid-
ered statistically significant.
miRNA target prediction
Using the results from differential gene and miRNA expres-
sion (cancer stem cells vs. cancer cells), gene–miRNAs 
interactions were predicted using seven miRNA target com-
putational prediction methods: MicroCosm (Version 5) 
[25], microT (version 3) [26], miRanda (August 2010 avail-
able at http://www.microrna.org/microrna/home.do) [27], 
miRDB (version 4.0) [28], PicTar (four-way) [29], PITA (ver-
sion 6) [30], and TargetScan (version 5.2) (with total context 
score >−0.3) [31]. Except for TargetScan, we used default 
cut-off values. Interactions that occurred in at least two of 
these sources were considered for downstream analyses.
Pathway enrichment analysis
Pathway enrichment analysis was employed to investigate 
the regulatory mechanisms of significantly differentially 
expressed miRNAs. KEGG and DAVID Bioinformatics 
Resources 6.7 databases were used for pathway enrich-
ment analyses. The enriched pathways were defined by 
their enrichment of significantly differentially expressed 
miRNA target genes. For DAVID functional annotation, 
the Fisher’s exact test was used to calculate statistical sig-
nificance (p values) of enriched annotation terms, where 
a smaller p value implies enrichment, and a p-value 
≤0.05 was deemed significant.
Results
Identification of candidate biomarkers in hepatic cancer 
stem cells
Differential expression analysis was used to identify can-
didate biomarkers in hepatic cancer stem cells. Using 
deep sequencing, miRNAs and genes differentially 
expressed between stem cells (Hep3B-C, Huh7-C) and 
the paired cancer cells from which they were derived 
(Hep3B, Huh7) were identified. Data normalization 
and differential expression analysis are described in the 
“Methods” section.
For miRNAs, 250 (59.7%) up- and 18 (4.3%) down-reg-
ulated miRNAs were identified in Hep3B-C cells, while 
23 (5.4%) up- and 128 (30.2%) down-regulated miRNAs 
were identified in Huh7-C cells. Finally, we selected 9 
up- and 9 down-regulated miRNAs, that were consist-
ently altered in both stem cell lines (compared with their 
corresponding cancer cells), as candidate miRNA bio-
markers of HCSCs (Fig. 2a). Using the same two paired 
samples, differential gene expression analysis was per-
formed, which produced 1928 (13.0%) up- and 4264 
(28.8%) down-regulated genes in Hep3B-C (vs. Hep3B) 
cells and 1933 (13.1%) up- and 1935 (13.1%) down-reg-
ulated mRNAs in Huh7-C (vs. Huh-7) cells. As shown 
in Fig. 2b, 115 and 402 genes were consistently up- and 
down-regulated, respectively in the two stem cell lines; 
these miRNAs and genes were used for downstream 
analyses (Additional file  1: Table  S1, Additional file  2: 
Table S2).
miRNA‑gene regulatory network analysis
To investigate the function of differentially expressed 
miRNAs, miRNA target genes were identified and 
miRNA target networks were constructed. First, seven 
miRNA target computational prediction methods were 
used to predict potential miRNA target genes, while con-
sidering all human genes as potential targets. This yielded 
54,933 miRNA–target interactions between 18 differen-
tially expressed miRNAs and 15,058 genes. To verify the 
miRNA–gene regulatory relationship in HCSCs, differ-
ential gene expression was considered in the context of 
miRNA–mRNA interaction whereby 1,460 miRNA–gene 
interactions between 16 and 398 differentially expressed 
miRNAs and differentially expressed genes were selected 
(Table  2). Considering the mechanism of miRNA-
mediated mRNA down-regulation, 651 miRNA–gene 
interactions between 7 up-regulated miRNAs and 274 
down-regulated genes, and 103 miRNA–gene interac-
tions between 9 down-regulated miRNAs and 62 up-reg-
ulated genes were selected (this workflow is summarized 
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Fig. 2 Differentially expressed miRNAs and genes. a, b illustrate the selection of differentially expressed miRNAs and genes, respectively between 
stem and cancer cells. Two paired stem- and cancer-cell samples (Hep3B-C, Hep3B) and (Huh7-C, Huh7) were used here; miRNAs and genes consist-
ently up- or down-regulated in both sample pairs were selected.
Table 2 Details of target genes regulated by differentially expressed miRNAs
Seven miRNA target computational prediction sources were used to identify the interactions of miRNAs and genes. The miRNA-target interactions which occurred in at least 














hsa-miR-100 Down 574 22 4 18 4
hsa-miR-210 Down 1180 33 5 28 5
hsa-miR-29c Down 3533 99 26 73 26
hsa-miR-181c Down 5492 141 15 126 15
hsa-miR-22* Down 2343 55 4 51 4
hsa-miR-15b* Down 1641 45 4 41 4
hsa-miR-199a-3p Down 3707 99 11 88 11
hsa-miR-199b-3p Down 3456 96 10 86 10
hsa-miR-149 Down 5100 116 24 92 24
hsa-miR-378d Up 7 0 0 0 0
hsa-miR-450b-5p Up 5865 146 8 138 138
hsa-miR-338-5p Up 5240 156 15 141 141
hsa-miR-760 Up 4249 113 32 81 81
hsa-miR-378 Up 3486 92 20 72 72
hsa-miR-215 Up 2878 81 11 70 70
hsa-miR-375 Up 3312 95 10 85 85
hsa-miR-1269b Up 12 0 0 0 0
hsa-miR-1269 Up 2877 71 7 64 64
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in Fig. 3). These interactions were then used as candidate 
miRNA–gene interactions to construct a miRNA–gene 
regulatory network (Fig. 4).
The network is an objective representation of all reg-
ulatory relationships between miRNAs and genes in 
HCSCs. Fig.  4a, b represent the regulatory networks of 
miRNAs up- and down-regulated in HCSCs compared 
with cancer cells, respectively. From Fig. 4, it is clear that 
up-regulated miRNAs interact with relatively more tar-
get genes compared with down-regulated miRNAs. Hsa-
miR-338-5p and hsa-miR-450b-5p, which have a large 
number of target genes, were the most important com-
ponents in the up-regulated miRNA regulatory network. 
In the down-regulated miRNA regulatory network, four 
target genes were exclusively regulated by has-miR-15b* 
and the down-regulated miRNA regulatory network 
could be divided into two sub networks. To identify the 
significance of this feature, the Fisher’s exact test was 
used here [32]. However there was no significant differ-
ence (p = 0.1149), suggesting that this feature may be the 
result of random chance. The importance of this feature 
requires further validation.
Using a ‘novel out degree’ (NOD), defined by Zhang 
et  al. [16], we measured the independent regulatory 
power of individual miRNAs. The NOD value repre-
sents the number of genes uniquely regulated by one 
Fig. 3 Workflow for the selection of candidate miRNA–gene interactions.
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specific miRNA. The distribution of miRNA NOD values 
is shown in Fig. 5. Consistent with the above result, there 
were more up-regulated miRNAs with large NOD values. 
The up-regulated miRNAs had larger independent regu-
latory power.
Analysis of stem‑cell‑associated miRNA pathways
Investigating miRNA-regulated pathways should help 
uncover the underlying mechanisms of stem cells. Using 
KEGG pathways, we performed enrichment analysis to 
identify stem-cell-related pathways. Significantly enriched 
KEGG pathways (p value <0.05) are shown in Table 3. To 
investigate the relevance of these pathways to cancer, we 
searched PubMed for published papers describing the 
roles of these pathways; published cancer-associated-func-
tions are listed in Table 4. Five pathways, enriched with up-
regulated miRNA targets, reportedly participate in tumor 
invasion and metastasis; these pathways are Cytokine-
cytokine receptor interaction, Regulation of actin cytoskel-
eton, Focal adhesion, Axon guidance, and Adipocytokine 
Fig. 4 miRNA regulatory network constructed with candidate miRNA–gene interactions. a shows the up-regulated miRNA regulatory network, 
which consists of 7 up-regulated miRNAs and 274 down-regulated genes. b shows the down-regulated miRNA regulatory network, which consists 
of 9 down-regulated miRNAs and 62 up-regulated genes. Pink nodes represent miRNAs and blue nodes represent genes. The size of miRNAs repre-
sents the number of candidate target genes; edges represent the relationship between miRNAs and genes.
Fig. 5 Distribution of miRNAs with different NODs. This figure shows the distribution of miRNAs with different NODs. NOD, defined in Zhang et al. 
[16], refers to the number of genes uniquely regulated by one specific miRNA. It characterizes the independent regulatory power of individual 
miRNAs.
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signaling pathway. Another important cancer-related 
pathway, MAPK signaling pathway, was also enriched 
with up-regulated miRNA targets. To study the function 
of up-regulated miRNAs in the context of these cancer-
related pathways, we constructed miRNA-gene-pathway 
regulatory networks. Fig.  6a shows the network for the 
five pathways related to tumor invasion and metastasis. 
Fig. 6b shows the network for the MAPK signaling path-
way, which is involved in HCC growth and survival. In 
these six cancer-related pathways, four genes (IL8, PRLR, 
EFNA1, and CHP2) were uniquely regulated by one spe-
cific miRNA each (hsa-miR-338-5p_IL8, hsa-miR-338-5p_
PRLR, hsa-miR-760_EFNA1, hsa-miR-450b-5p_CHP2).
However, two pathways, Terpenoid backbone biosyn-
thesis (hsa00900) and Synthesis and degradation of ketone 
bodies (hsa00072), have not previously been related to 
cancer. These two pathways were enriched with the target 
genes of down-regulated miRNAs (hsa00900_hsa-miR-
181c, has-miR-29c, hsa00072_hsa-miR-29c). The net-
work of these two pathways is shown in Fig. 6c.
Discussion
To better understand the characteristics of HCSCs 
established in our lab, we identified differentially 
expressed miRNAs and genes in HCSCs compared with 
hepatic cancer cells based on high-throughput sequenc-
ing datasets (9 up-regulated miRNAs; 9 down-regulated 
miRNAs; 115 up-regulated genes; 402 down-regulated 
genes). The relationship between these miRNAs and 
genes, and their pathway-level involvement were ana-
lyzed. With the aim of investigating regulatory mecha-
nisms in HCSCs, we constructed regulatory networks 
based on candidate biomarkers and enriched pathways 
in HCSCs.
We found a complex relationship between dif-
ferentially expressed miRNAs and genes in HCSCs. 
MiRNA–gene regulatory networks were constructed, 
and up-regulated miRNAs were found to regulate 
more target genes and have larger NOD values com-
pared with down-regulated miRNAs. This implies that 
up-regulated miRNAs might be more important in the 
regulation of HCSCs. We identified two up-regulated 
miRNAs (hsa-miR-338-5p, and hsa-miR-450b-5p) that 
down-regulate hundreds of genes. The number of tar-
gets for hsa-miR-338-5p and hsa-miR-450b-5p were 
141 and 138, respectively. The association of these two 
miRNAs with HCC and HCSCs has not previously been 
reported. Our results were obtained by computational 
methods only and further experimental validation is 
therefore required.
Table 3 Significantly enriched KEGG pathways (p-value <0.05)
KEGG database and DAVID Bioinformatics Resources 6.7 were used for pathway enrichment analyses of genes regulated by identified HCSC miRNA biomarkers. 
Significant enriched pathways (P value <0.05) are listed in this table.
miRNA Term_ID Term_name Gene_count Genes P‑value
hsa-miR-29c hsa00900 Terpenoid backbone biosynthesis 3 HMGCR, HMGCS1, HMGCS2 0.00023
hsa-miR-29c hsa00072 Synthesis and degradation of ketone bodies 2 HMGCS1, HMGCS2 0.014
hsa-miR-181c hsa00900 Terpenoid backbone biosynthesis 2 HMGCR, HMGCS1 0.012
hsa-miR-338-5p hsa05200 Pathways in cancer 10 RARB, FZD4, ITGA2, IL8, FGF12, DAPK1, EGLN3, 
PDGFRA, LAMC2, FGF11
0.0036
hsa-miR-338-5p hsa04510 Focal adhesion 7 CAV1, CAV2, ITGA2, LAMC2, MYLK3, PDGFRA, VAV3 0.012
hsa-miR-338-5p hsa04810 Regulation of actin cytoskeleton 7 VAV3, MYLK3, PDGFRA, ITGA2, FGF11, TIAM2, FGF12 0.016
hsa-miR-338-5p hsa04920 Adipocytokine signaling pathway 4 JAK2, ACSL4, PPARGC1A, PRKAB2 0.026
hsa-miR-338-5p hsa04060 Cytokine-cytokine receptor interaction 7 CXCL12, GHR, INHBB, IL8, PDGFRA, PRLR, TNFSF4 0.038
hsa-miR-378 hsa04510 Focal adhesion 5 COL6A2, ITGA2, MYLK3, PDGFRA, VAV3 0.0058
hsa-miR-378 hsa04810 Regulation of actin cytoskeleton 5 VAV3, MYLK3, PDGFRA, ITGA2, FGF12 0.0073
hsa-miR-378 hsa04060 Cytokine-cytokine receptor interaction 5 CXCL12, EPO, INHBB, PDGFRA, TGFB2 0.014
hsa-miR-378 hsa05200 Pathways in cancer 5 FGF12, FZD4, ITGA2, PDGFRA, TGFB2 0.03
hsa-miR-378 hsa05210 Colorectal cancer 3 FZD4, PDGFRA, TGFB2 0.038
hsa-miR-760 hsa04060 Cytokine-cytokine receptor interaction 6 CXCL12, EPO, INHBB, PDGFRA, TGFB2, TNFSF4 0.011
hsa-miR-760 hsa05200 Pathways in cancer 6 EGLN3, FGF11, FZD4, PDGFRA, TGFB2, RALB 0.027
hsa-miR-760 hsa04360 Axon guidance 4 CXCL12, EFNA1, NTN4, SEMA7A 0.03
hsa-miR-215 hsa05200 Pathways in cancer 6 FGF11, FGF12, FZD4, ITGA2, LAMC2, RALB 0.014
hsa-miR-450b-5p hsa04060 Cytokine-cytokine receptor interaction 7 IL1R1, EPO, CXCL12, TNFSF4, TGFB2, PDGFRA, GHR 0.029
hsa-miR-450b-5p hsa04010 MAPK signaling pathway 7 IL1R1, DUSP10, TGFB2, PDGFRA, CHP2, MAP3K8, 
FGF12
0.032
hsa-miR-450b-5p hsa04810 Regulation of actin cytoskeleton 6 TIAM2, FGF12, IGF2, ITGA2, PDGFRA, VAV3 0.043
Page 8 of 10Ding et al. J Transl Med  (2015) 13:259 
Table 4 Published cancer-associated functions of enriched pathways
We searched PubMed for published papers to explain the relevance of significantly enriched pathways to cancer. The published cancer-associated-functions of these 
pathways are listed in this table.
Term_ID miRNAs Term_name Relevance to cancer
hsa05200 hsa-miR-215,hsa-miR-338-5p,  
hsa-miR-378,hsa-miR-760
Pathways in cancer
hsa04060 hsa-miR-338-5p,hsa-miR-378,  
hsa-miR-450b-5p,hsa-miR-760
Cytokine-cytokine receptor interaction Cytokines can control invasion and metastasis, 
and also function to inhibit tumor progres-
sion [40]
hsa04810 hsa-miR-338-5p,hsa-miR-378,  
hsa-miR-450b-5p
Regulation of actin cytoskeleton Several studies revealed that molecules that 
link migratory signals to the actin cytoskel-
eton are upregulated in invasive and meta-
static cancer cells [41]
hsa04510 hsa-miR-338-5p, hsa-miR-378 Focal adhesion Focal adhesion kinase, which plays an 
important role in tumor progression and 
metastasis, is overexpressed and activated in 
a variety of human cancers [42, 43]
hsa04010 hsa-miR-450b-5p MAPK signaling pathway The MAPK pathway plays an important role 
in HCC in that its activation is reportedly 
involved in HCC growth and survival [35]
hsa04360 hsa-miR-760 Axon guidance The ligand/receptor pairs of axon guidance 
regulate tumor angiogenesis [44]
hsa04920 hsa-miR-338-5p Adipocytokine signaling pathway Adipocytokine signaling pathway has been 
demonstrated participate in breast cancer 
progression [45]
hsa05210 hsa-miR-378 Colorectal cancer
hsa00900 hsa-miR-181c, hsa-miR-29c Terpenoid backbone biosynthesis
hsa00072 hsa-miR-29c Synthesis and degradation of ketone bodies
Fig. 6 miRNA–gene–pathway regulatory networks. a shows the network for five pathways related to tumor invasion and metastasis. b shows the 
network for the MAPK signalling pathway. c shows the network for two new pathways, which have not been previously associated with cancer. MiR-
NAs, genes, and pathways are represented by nodes (pink miRNAs; green genes; and blue pathways). Edges of dark color represent the relationship 
between genes and pathways; and edges of light color represent the relationship between miRNAs and genes. Nodes marked with a red asterisk 
refer to genes uniquely regulated by one specific miRNA.
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Through functional analyses we uncovered impor-
tant biological processes involved in the regulation of 
HCSCs. Ten KEGG pathways were enriched in HCSCs. 
Pathway-level text mining was used to evaluate the rel-
evance of these enriched pathways in cancer. Interest-
ingly, five of the pathways have previously been reported 
to be involved in tumor invasion and metastasis. Inva-
sion and metastasis are the main causes of cancer deaths, 
and are complex multi-step processes [33, 34]. Pathway 
analysis results are supported by the fact that the HCSCs 
established in our lab have much stronger invasive capa-
bility than hepatic cancer cells. Four up-regulated miR-
NAs (hsa-miR-338-5p, hsa-miR-450b-5p, hsa-miR-378, 
and hsa-miR-760) were identified to take part in HCSC 
invasion-related pathways. Two genes, PDGFRA and 
CXCL12, that were regulated by all four invasion-related 
miRNAs and that are involved in several invasion-related 
pathways, might play important roles in the regulation 
of this process (Fig.  6a). Another cancer-related path-
way, MAPK signaling pathway, was also enriched with 
hsa-miR-450b-5p target genes. The MAPK signaling is a 
complex pathway involved in the regulation of a variety 
of growth and differentiation pathways and is reportedly 
involved in HCC growth and survival [35]. Four genes 
(IL8, PRLR, EFNA1, and CHP2) that were uniquely regu-
lated by specific miRNAs, have been associated with HCC 
[36–39]. However, the regulatory mechanism of these 
genes in HCSCs requires further investigation. In addition 
to known cancer-related pathways, we also identified two 
novel HCSC-related pathways, Terpenoid backbone bio-
synthesis and Synthesis and degradation of ketone bodies. 
These two pathways were enriched with down-regulated 
miRNA target genes in HCSCs. Terpenoids are a large 
class of natural products consisting of isoprene units, 
while ketone bodies are produced by the liver from fatty 
acids and used peripherally as an energy source when 
glucose is not readily available. Their relevance to HCC 
and HCSCs has not been reported, and requires further 
validation.
We globally analyzed the molecular expression signature 
and regulatory mechanisms in HCSCs established in our 
lab. Although we have identified candidate molecular mark-
ers and important pathways in HCSCs, our results are pre-
liminary and further experimental validation is required.
Conclusions
Using high-throughput sequencing data sets and 
bioinformatics analyses, we identified miRNA and 
mRNA signatures of HCSCs. Additionally, we com-
bined miRNA, mRNA, and pathway analyses to study 
the regulatory mechanisms in HCSCs by constructing 
miRNA–mRNA and miRNA–mRNA–pathway regu-
latory networks. The molecular markers and pathways 
identified herein might be used as candidate biomark-
ers and drug targets for the diagnosis and treatment of 
hepatic cancer.
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